Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs

With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment settings is increasing rapidly. Although some patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tian, Forde, Patrick M, Sullivan, Ryan J, Sharon, Elad, Barksdale, Elizabeth, Selig, Wendy, Ebbinghaus, Scot, Fusaro, Gina, Gunenc, Damla, Battle, Dena, Burns, Robyn, Hurlbert, Marc S, Stewart, Mark, Atkins, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163527/
https://www.ncbi.nlm.nih.gov/pubmed/37137552
http://dx.doi.org/10.1136/jitc-2022-006555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163527/
https://www.ncbi.nlm.nih.gov/pubmed/37137552
http://dx.doi.org/10.1136/jitc-2022-006555

Ejemplares similares